LivQ-box® Parameters in the Diagnosis of Liver Inflammation
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorWuxi Hisky Medical Technology Co Ltd
About this trial
To evaluate the correlation between LivQ-box® parameters carried by iLivTouch and liver inflammation in patients with NAFLD, as well as the diagnostic value of liver inflammation of different severity levels.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients diagnosed with NAFLD according to The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases;
Age over 18 years old, gender not limited;
Not combined with liver diseases (such as viral hepatitis, drug-induced liver injury, autoimmune liver disease);
Perform iLivTouch examination within ± 14 days of liver pathology examination;
Disqualifiers
None
Trial population
Patients diagnosed with NAFLD according to The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Evaluate the correlation and diagnostic performance of LivQ-box and cut-off values for different inflammation stages in NAFLD patients based on iLivTouch.
Time frame
12 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Wuxi Hisky Medical Technology Co Ltd
Lead sponsor
Beijing Tsinghua Changgeng Hospital
Collaborator
Source ClinicalTrials.gov